GALDY FINANCIAL STATEMENTS

GALDERMA GROUP AG — balance sheet, income statement and cash flow trends

GALDYGALDERMA GROUP AG

🇺🇸 USA · US · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

Profit Funnel

Q2 2025 · TTM

Key Figures

YoY change

Revenue——

Gross Profit——

Operating Income——

EBITDA——

Net Income——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
GALDY	—	—	—	—
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q2 2025

Equity8.2 B $61%
Current Liabilities2.1 B $15%
Long-term Liabilities3.2 B $24%

Key Figures

YoY change

Total Assets13.4 B $+7.4%

Total Liabilities5.2 B $-26.2%

Total Equity8.2 B $+51.8%

Cash & ST Investments——

Total Debt——

Net Debt1.8 B $-58.7%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
GALDY	1.19	—	—	60.9%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Cash Flow Bridge

Q2 2025 · TTM

Key Figures

YoY change

Operating Cash Flow——

Capital Expenditures——

Free Cash Flow——

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
GALDY	—	—	—	—
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on GALDY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.